Year 2019, Volume 58 , Issue , Pages 27 - 33 2019-10-25

Rational use of analgesics with regard to the interactions with disease-modifying anti-rheumatic drugs
Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı

Aytül Önal [1]


In the inflammatory rheumatic diseases, analgesics, especially the NSAIDs are the most used drugs with the disease-modifying anti-rheumatic drugs (DMARDs). The controlled studies which were done related with the interactions between the aforementioned drugs are not too many and they are more related with interactions between methotrexate and NSAIDs. Controlled studies are mostly needed related with the interactions between analgesic drugs and biologic DMARDs which were especially came into use in the recent years. In our review, rational use of drugs was mentioned with regard to the interaction between DMARDs and analgesic drugs. These interactions were presented as subtitles related with changes in binding to proteins, renal, gastrointestinal system, hematologic, hepatic functions and the levels of enzymes.

İnflamatuar nitelikli romatizmal hastalıklarda, analjezikler özellikle de NSAİİ’ler “Hastalığı modifiye eden antiromatizmal ilaçlar (Disease-Modifying Anti-Rheumatic drugs; DMARDs)” ile birlikte sıklıkla kullanılan ilaçlardandır. Söz konusu ilaçlar arasındaki etkileşimler ile ilgili yapılmış kontrollü çalışmalar çok değildir ve daha çok metotreksat ve NSAİİ’ler arasındaki etkileşimler ile ilgilidir. Özellikle son yıllarda kullanımı artan biyolojik DMARD’ler ile analjezik ilaçlar arasındaki etkileşmelere yönelik kontrollü araştırmalara büyük ihtiyaç vardır. Derlememizde, DMARD’ler ile analjezik ilaçlar arasındaki etkileşimler bakımından akılcı ilaç kullanımından söz edilmiştir. Bu etkileşimler, proteine bağlanma, renal, gastrointestinal, hematolojik, hepatik fonksiyonlar ve enzim düzeyindeki değişimler ile ilgili alt başlıklar şeklinde sunulmuştur.

  • Düzgün N. Romatizmal Hastalıkların Tanımı ve Sınıflandırılması. Türkiye Klinikleri J Immunol Rheumatol 2002;2(1):3-5.
  • World Health Organization (Geneva, 1987). The rational use of drugs. Report of the Conference of Experts, Nairobi, 25- 29 November 1985.
  • Kayaalp SO. İlaçlar Arasındaki Etkileşmeler. Ed: Kayaalp SO. Akılcı Tedavi Yönünden Tıbbi Farmakoloji. 13. Baskı, 1. Cilt. Pelikan Yayıncılık; 2012:104.
  • Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Australian Prescriber 2012;35(3):85-8.
  • Brunton LL, Hilal-Dandan R. İnflamasyon, Ateş, Ağrı ve Gut Farmakoterapisi. Ed: Erdem ŞR. Goodman and Gilman’ın Farmakoloji ve Tedavi El Kitabı 2. Baskı. Güneş Tıp Kitapevleri; 2017:587-613.
  • Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960-77.
  • Gülbezer EE, Keser G. Biyolojik tedaviler. RAED Journal 2017;9(1–2):11–31.
  • Keleşoğlu AB, Karadağ O. Romatolojik Hastalıklarda Kullanılan İmmünsüpresif İlaçlar (Siklofosfamid, Azatiyopirin, Mikofenolat Mofetil, Takrolimus). Türkiye Klinikleri J Rheumatol-Special Topics 2015;8(3):21-7.
  • Whittle SL, Colebatch AN, Buchbinder R et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012;51(8):1416-25. [PubMed:22447886].
  • Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep 2013;15(1):300. [PubMed:23292816].
  • Bagatini F, Blatt CR, Maliska G et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011 Jan-Feb;51(1):20-39. [PubMed: 21412604]
  • Fendrick AM, Pan DE, Johnson GE. OTC analgesics and drug interactions: clinical implications. Osteopath Med Prim Care 2008;2:2. [PubMed: 18257920]
  • Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep 1985 Mar;69(3):342 3. [PubMed:3978662]
  • Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986;327(8494):1390. [PubMed:2872506]
  • Brogden RN. Nonsteroidal anti-inflammatory analgesics other than salicylates. Drugs 1986;32 (Suppl 4):27-45. [PubMed: 3552584]
  • Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methrotrexate and ketoprofen. Lancet 1986; 327(8475):256-8 [PubMed: 2868265]
  • Singh RR, Malaviya AN, Pandey JN. Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet 1986; 327(8494):1390 [PubMed:2872507]
  • Adams JD, Hunter GA. Drug interactions in psoriasis. Australas J Dermatol 1976;17(2):39-40. [PubMed:1022213]
  • Daly H, Boyle J, Roberts C, Scott G. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs. Lancet 1986; 327(8480): 557 [PubMed: 2869282]
  • Liegler DG, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10(6):849-57. [PubMed:5349626]
  • Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30(3):194–210. [PubMed:8882301]
  • Statkevich P, Fournier DJ, Sweeney KR. Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993;265(3):1118-24. [PubMed: 8509997]
  • Takeda M, Khamdang S, Narikawa S et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302(2):666-71. [PubMed: 12130730]
  • Uwai Y, Saito H, Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 2000;409(1):31-6. [PubMed:11099697]
  • Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 1990;47(4):540-6. [PubMed:2328562]
  • Johnson AG, Seideman P, Day RO. Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance. Drug Saf. 1993;8(2):99-127. [PubMed:8452660]
  • Stewart CF, Evans WE. Drug-drug interactions with antirheumatic agents: review of selected clinically important interactions. J Rheumatol Suppl 1990;22:16-23 [PubMed: 2192056]
  • Weinblatt ME. Drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl 1989;83:7-10. [PubMed: 2576330]
  • Fischetti LF. Interaction between nonsteroidal anti-inflammatory drugs and high-dose methotrexate: a literature review. J Pediatr Oncol Nurs 1990;7(1):14-6 [PubMed:2194502]
  • Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol(acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;11:CD008872. [PubMed:22071858]
  • Lifschitz MD. Prostaglandins and renal blood flow: in vivo studies. Kidney Int 1981;19(6):781-5. [PubMed:6790809]
  • Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563-72. [PubMed: 6363936]
  • Schnermann J, Briggs JP. Participation of renal cortical prostaglandins in the regulation of glomerular filtration rate. Kidney Int 1981;19(6):802-15. [PubMed:7021955]
  • Dunn MJ, Simonson M, Davidson EW, Scharschmidt LA, Sedor JR. Nonsteroidal anti-inflammatory drugs and renal function. J Clin Pharmacol 1988;28(6):524-9. [PubMed:3047178]
  • Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum. 1985;14(3):163-75. [PubMed:3909403]
  • Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A. Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol. 1987;27(4):213-4. [PubMed:2953512]
  • Sturrock ND, Lang CC, Struthers AD. Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens. 1994;12(8):919-24. [PubMed:7814851]
  • Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant induced nephropathy: pathophysiology, incidence and management. Drug Saf. 1999;21(6):471-88. [PubMed:10612271]
  • Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med. 1992;93(4):396-402. [PubMed:1415303]
  • Harris KP, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine. A potentially serious adverse interaction. Transplantation. 1988;46(4):598-9. [PubMed:3176159]
  • Williamson HE. Interaction of cyclosporine and indomethacin in the rat. Res Commun Chem Pathol Pharmacol. 1988;61(1):141-4. [PubMed:3262905]
  • Helmy MW, El-Gowelli HM, Ali RM, El-Mas MM. Endothelin ETA receptor/lipid peroxides/COX-2/TGF-β1 signalling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats. Br J Pharmacol. 2015;172(17):4291-302. [PubMed:26013701]
  • Kovarik JM, Mueller EA, Gerbeau C, Tarral A, Francheteau P, Guerret M. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. Life Sci 2017 Sep 15;185:15-22
  • El-Gowelli HM, Ibrahim KS, El-Yazbi AF, El-Mas M.M. Role of NADPHox/Rho-kinase signaling in the cyclosporine-NSAIDs interactions on blood pressure and baroreflexes in female rats. J Clin Pharmacol. 1997;37(4):336-43. [PubMed:9115060]
  • El-Yazbi AF, Eid AH, El-Mas MM. Cardiovascular and renal interactions between cyclosporine and NSAIDs: Underlyingmechanisms and clinical relevance. Pharmacol Res. 2018;129:251-261. [PubMed:29183768]
  • Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24(3):330-50. [PubMed:11952020]
  • Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet. 1996;30(2):141-79. [PubMed:8906896]
  • Ludwin D. Cyclosporine monitoring in autoimmune and other diseases. Clin Biochem. 1991;24(1):97-9. [PubMed:2060141]
  • Naesens M, Lerut E. Calcineurin Inhibitor Nephrotoxicity in the Era of Antibody-Mediated Rejection. Transplantation. 2016;100(8):1599-600. [PubMed:27306528]
  • Soubhia RM, Mendes GE, Mendonça FZ, Baptista MA, Cipullo JP, Burdmann EA. Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided. Am J Nephrol. 2005;25(4):327-34. [PubMed:15976495]
  • Nierenberg DW. Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1983;226(1):1-6. [PubMed:6864533]
  • Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokineticsin patients with rheumatoid arthritis. J Rheumatol. 1999;26(12):2539-43. [PMID:10606360]
  • Maeda A, Tsuruoka S, Ushijima K et al. Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfectedrenal cells and in rats in vivo. Eur J Pharmacol. 2010;640(1-3):168-71. [PubMed:20478302]
  • Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2inhibitor. Clin Pharmacokinet. 2000;38(3):225-42. [ PubMed:10749518]
  • Webberley MJ, Murray JA. Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin. Postgrad Med J. 1989;65(770):950-2. [PubMed:2616440]
  • Raschi E, Piccinni C, Signoretta V et al. Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. Br J Clin Pharmacol. 2015;80(6):1411-20. [PubMed:26303150]
  • Masclee GM, Valkhoff VE, Coloma PM et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-792. [PubMed:24937265]
  • Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis. 2003;62(11):1033-7. [PubMed:14583563]
  • Bertsche T, Mikus G. Adverse drug reactions and drug interactions in analgesic therapy. Ther Umsch. 2011;68(1):19-26. [PubMed:21184390]
  • Siu YA, Hao MH, Dixit V, Lai WG. Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227. [PubMed:30219715]
  • Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41(6):421-30. [PubMed:12074690]
  • Stobbe H, Hüge W. Hematotoxic lesions caused by non-steroidal antirheumatic agents. Z Gesamte Inn Med. 1980;35(23):165-9. [PubMed:7467611]
  • U.S. Food and Drug Administration. CUPRIMINE® (Penicillamine). 2004. MERCK&CO. INC. Whitehouse Station, NJ 08889, USA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf
  • Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004;20(4):373-80. [PubMed:15298630]
  • Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):563-75. [PubMed:17723920]
  • Pérez Gutthann S, García Rodríguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology. 1993;4(6):496-501. [PubMed:8268277]
  • Anelli MG, Scioscia C, Grattagliano I, Lapadula G. Old and new antirheumatic drugs and the risk of hepatotoxicity. Ther Drug Monit. 2012 Dec;34(6):622-8.
  • U.S Food and Drug Administration. CIMZIA® (Certolizumab pegol) 2018. UCB INC. Smyrna, GA 30080, USA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125160s283lbl.pdf.
  • The electronic Medicines Compendium (eMC) CIMZIA® (Certolizumab pegol) 2018. UCB Pharma Limited, Slough, Berkshire, SL1 3WE, UK. https://www.medicines.org.uk/emc/product/7387/smpc.
  • U.S Food and Drug Administration. ENBREL® (Etanercept) 2018. AMGEN INC. Thousand Oaks, CA 91320-1799, USA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103795s5569lbl.pdf.
  • The electronic Medicines Compendium (eMC) BENEPALI® (Etanercept) 2018. Biogen Idec Ltd. Maidenhead, Berkshire, SL6 4AY, UK. https://www.medicines.org.uk/emc/product/1987/smpc.
  • U.S Food and Drug Administration. ACTEMRA® (Tocilizumab) 2018. GENENTECH INC. South San Francisco, CA 94080-4990, USA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125276s118,125472s029lbl.pdf.
  • The electronic Medicines Compendium (eMC) ROACTEMRA® (Tocilizumab) 2018 ROCHE Product Limited, Welwyn Garden City, Hertfordshire, AL7 1TW, UK. https://www.medicines.org.uk/emc/product/9086/smpc.
Primary Language tr
Subjects Health Care Sciences and Services
Journal Section Supplement
Authors

Orcid: 0000-0002-7273-1131
Author: Aytül Önal (Primary Author)
Institution: Ege Üniversitesi Tıp Fakültesi, Tıbbi Farmakoloji Anabilim Dalı
Country: Turkey


Dates

Publication Date : October 25, 2019

Bibtex @other { etd648718, journal = {Ege Tıp Dergisi}, issn = {1016-9113}, eissn = {2147-6500}, address = {}, publisher = {Ege University}, year = {2019}, volume = {58}, pages = {27 - 33}, doi = {10.19161/etd.648718}, title = {Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı}, key = {cite}, author = {Önal, Aytül} }
APA Önal, A . (2019). Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı. Ege Tıp Dergisi , 58 () , 27-33 . DOI: 10.19161/etd.648718
MLA Önal, A . "Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı". Ege Tıp Dergisi 58 (2019 ): 27-33 <http://egetipdergisi.com.tr/en/issue/50237/648718>
Chicago Önal, A . "Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı". Ege Tıp Dergisi 58 (2019 ): 27-33
RIS TY - JOUR T1 - Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı AU - Aytül Önal Y1 - 2019 PY - 2019 N1 - doi: 10.19161/etd.648718 DO - 10.19161/etd.648718 T2 - Ege Tıp Dergisi JF - Journal JO - JOR SP - 27 EP - 33 VL - 58 IS - SN - 1016-9113-2147-6500 M3 - doi: 10.19161/etd.648718 UR - https://doi.org/10.19161/etd.648718 Y2 - 2019 ER -
EndNote %0 Ege Tıp Dergisi Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı %A Aytül Önal %T Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı %D 2019 %J Ege Tıp Dergisi %P 1016-9113-2147-6500 %V 58 %N %R doi: 10.19161/etd.648718 %U 10.19161/etd.648718
ISNAD Önal, Aytül . "Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı". Ege Tıp Dergisi 58 / (October 2019): 27-33 . https://doi.org/10.19161/etd.648718
AMA Önal A . Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı. Ege Tıp Dergisi. 2019; 58: 27-33.
Vancouver Önal A . Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı. Ege Tıp Dergisi. 2019; 58: 33-27.